Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 7, 2004, Pages 811-815

  Aaron, Shawn D ^a   Ramotar, Karam ^b   Ferris, Wendy ^b   Vandemheen, Katherine ^b   Saginur, Raphael ^b   Tullis, Elizabeth ^b   Haase, David ^b   Kottachchi, Dan ^b   St Denis, Melissa ^b   Chan, Francis ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

Cystic fibrosis; Lung infection; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; SPUTUM CULTURE;

EID: 12144288633     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200309-1306oc     Document Type: Article

References (28)

1. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017.
2. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
3. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
4. Cystic Fibrosis Foundation. Microbiology and infectious disease in cystic fibrosis: V [section 1]. Bethesda, MD: Cystic Fibrosis Foundation; 1994.
5. Regelmann W, Elliott G, Warwick W, Clawson C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
6. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Redding G, Rubio T, et al. CF comparison of a b-lactam alone versus b-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999;134:413-421.
7. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-689.
8. Sethi S, Evans N, Brydon JB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
9. Saiman L, Burns JL, Whittier S, Krzewinski J, Marshall SA, Jones RN. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis. J Clin Microbiol 1999;37:2987-2991.
10. Laing FPY, Ramotar K, Read RR, Alfieri NN, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995;33:513-518.
11. Tenover FC, Arbeit RD, Goering RV. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial stain typing. J Clin Microbiol 1995;33:2233-2239.
12. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:1129-1135.
13. Govan JRW, Doherty C, Glass S. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 1987;15:307.
14. Grothues D, Koopman U, Hardt HVD, Tummler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1998;26: 1973-1977.
15. Seale TW, Thirkill H, Tarpay M, Flux M, Rennert OM. Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolated from single sputa of cystic fibrosis patients. J Clin Microbiol 1979;9:72-78.
16. Thomassen MJ, Demko CA, Boxerbaum B, Stern RC, Kuchenbrod PJ. Multiple isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis. J Infect Dis 1979;140:873-880.
17. Breitenstein S, Walter S, Bosshammer J, Romling U, Tummler B. Direct sputum analysis of Pseudomonas aeruginosa macrorestriction fragment genotypes in patients with cystic fibrosis. Med Microbiol Immunol 1997;186:93-99.
18. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452.
19. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
20. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
21. Ratjen F, Doring G, Nikolaizik H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-984.
22. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
23. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002;40: 4172-4179.
24. Hoiby N. New antimicrobials in the management of cystic fibrosis. J Antimicrob Chemother 2002;49:235-238.
25. Struelens MJ, Schwam V, Delpano A, Baran D. Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients. J Clin Microbiol 1993;31:2320-2326.
26. Romling U, Grouthues D, Koopman, Jahnke B, Greipel J, Tummler B. Pulsed-field gel electrophoresis analysis of a Pseudomonas aeruginosa pathovar. Electrophoresis 1992;13:646-648.
27. Silbert S, Barth AL, Sader HS. Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients. J Clin Microbiol 2001;39:3976-3981.
28. Boukadida J, De Montalembert M, Lenoir G, Scheinmann P, Veron M, Berche P. Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis. J Med Microbiol 1993;38: 29-33.